NIVF — NewGenIvf Income Statement
0.000.00%
Last trade - 00:00- $4.00m
- $6.02m
- $5.43m
Annual income statement for NewGenIvf, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 4.12 | 5.94 | 5.14 | 5.43 |
| Cost of Revenue | ||||
| Gross Profit | 1.02 | 1.54 | 1.68 | 1.83 |
| Selling / General / Administrative Expenses | ||||
| Total Operating Expenses | 3.92 | 5.55 | 5.09 | 6.59 |
| Operating Profit | 0.199 | 0.399 | 0.042 | -1.16 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | 0.156 | 0.344 | 0.108 | -0.961 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -0.139 | 0.136 | 0.108 | -0.474 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | -0.001 | 0.459 | 0.13 | -0.525 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -0.001 | 0.459 | 0.13 | -0.525 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.011 | 9.04 | 2.57 | -4.61 |
| Dividends per Share |